Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the United States and second-leading cause of cancer death.
1 Colorectal cancer outcomes vary by race and socioeconomic status (SES), with African American individuals and individuals with low SES having higher incidence and mortality than other groups. Most CRCs arise from noncancerous, adenomatous polyps.
2 Colorectal cancer screening programs aim to intervene in the cancer progression process by the detection and subsequent removal of polyps before they progress to cancer and by early detection of CRCs in asymptomatic individuals. The importance of CRC screening by visual- and stool-based screening modalities for reducing CRC incidence and mortality has been demonstrated in randomized clinical trials and cohort studies.
3-8 Cohort studies provide opportunities to evaluate the effectiveness of CRC screening in targeted populations. A previous cohort study
5 of data from follow-up of nurses and other health care professionals reported 40% to 56% lower CRC incidence among participants screened through lower endoscopy (colonoscopy or sigmoidoscopy) compared with participants who had never undergone lower endoscopy screening, and a 68% reduction in colorectal cancer mortality among participants who had undergone screening colonoscopy. Stool-based screening programs, such as fecal occult blood tests (FOBTs) and fecal immunochemical tests, have also been shown to be effective for detecting colorectal polyps and cancers.
8 Randomized clinical trials of stool-based screening modalities have found reduced CRC incidence and mortality among patients with abnormal stool-based screening findings who underwent diagnostic colonoscopy and polypectomy.
8,9